Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| OANMX | 156.25 | 0.08 | +0.05% |
| Oakmark Institutional | |||
| IMRFX | 14.10 | -0.03 | -0.21% |
| Columbia Global Opportunities A | |||
| LCGJX | 29.49 | -0.11 | -0.37% |
| William Blair Large Cap Growth R6 | |||
| IAFLX | 18.38 | -0.14 | -0.76% |
| F/m Investments Large Cap Focused Inst | |||
| CWVIX | 26.22 | -0.21 | -0.79% |
| Calvert International Equity I | |||
A.I.dvisor tells us that INTI and QRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTI and QRON's prices will move in lockstep.
| Ticker / NAME | Correlation To INTI | 1D Price Change % | ||
|---|---|---|---|---|
| INTI | 100% | N/A | ||
| QRON - INTI | 24% Poorly correlated | N/A | ||
| DWTX - INTI | 23% Poorly correlated | +2.08% | ||
| IVEVF - INTI | 17% Poorly correlated | N/A | ||
| IVBXF - INTI | 11% Poorly correlated | N/A | ||
| HSTC - INTI | 8% Poorly correlated | -5.55% | ||
More | ||||